Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma Inc.

The latest update is out from Vor Biopharma ( ($VOR) ). At its 2026 Annual Meeting, Vor Biopharma stockholders elected Andrew Levin, M.D., Ph.D., a...

Vor Biopharma shareholders back directors and governance measures

The latest announcement is out from Vor Biopharma ( ($VOR) ). Vor Bio and its collaborator RemeGen Co., Ltd. reported on June 8, 2026, that China’s...

Vor Bio gains boost from telitacicept IgA nephropathy approval

Vor Biopharma, Inc. ($VOR) announced an update on their ongoing clinical study. The phase 3 study called “A Multicenter, Randomized, Double-Blind, ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VOR	$14.49	-3.53%	2.88M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VOR	$14.49	-3.5%	2.88M
3
4
5
6

VOR

VOR

Recent News for VOR

Get Vor Biopharma Inc. Data in Excel

Get Vor Biopharma Inc. Data in Excel